Accedi a banche dati online | Convegnodetail
mail
Anteprima di stampa
 
 

7th Neuropsychiatric Drug Development Summit

Evvnt Promotion / evvnt
-
24.09.2024 - 26.09.2024  Hilton Boston Back Bay, 40 Dalton Street, 02115 Boston, Massachusetts, USA
Time: 8:00 AM - 5:00 PM
 
Temi della conferenza
With Karuna's schizophrenia program coined as the most anticipated drug launch of 2024, and 2023 bringing brand new regulatory guidance, surging investment has reinvigorated the space with new targets, mechanisms, and technologies to transform the mental health treatment landscape.
Professional congress organizer (PCO)
Hanson Wade Group
Annotazioni
URL:
Brochure: https://go.evvnt.com/2433814-3?pid=4832

Speakers: Aaron Koenig, Chief Medical Officer, Delix Therapeutics, Ariana Mullin, Director, Regulatory Affairs, Bristol Myers Squibb, and more
 

Informazioni ed Iscrizioni:

https://go.evvnt.com/2433814-2?pid=4832
Ms. Erin Thomas
 
Categorie
Medicina General
Lingua
Inglese
Quote del Congresso
Drug Developer Pricing - Conference + Workshop Day: USD 3597.00, Drug Developer Pricing - Conference Only: USD 2599.00, Solution Provider Pricing - Conference + Workshop Day: USD 5197.00, Solution Provider Pricing - Conference Only: USD 3699.00
Contatto organizzatori
83 Great Titchfield Street
W1W 6RH London
United Kingdom
 
"Noi, Going International, siamo un’azienda che si è scelta come obiettivo di rendere acessibile la formazione a una grandissima quantità di persone, oltrepassanddo i confini geografici e sociali."

Helix - Forschung & Beratung WiennewTreeEuropean Public Health Association (EUPHA)European Health Forum GasteinCentro per la Formazione Permanente e l'Aggiornamento del Personale del Servizio SanitarioAGEM - Arbeitsgemeinschaft Ethnologie und MedizinÄrzte der WeltCharité International Academy